Tezepelumab improves patient-reported outcomes in patients with severe, uncontrolled asthma in PATHWAY

• DOI: 10.1016/j.anai.2020.10.008
• Publication Date: 2020-10-23T16:51:35Z
• Authors: Jonathan Corren; Esther Garcia Gil; Janet M. Griffiths; Jane R. Parnes; Rene van der Merwe; Kinga Sałapa; Sean O'Quinn
• Keywords: Adult; Male; 0301 basic medicine; Adolescent; Injections, Subcutaneous; Middle Aged; Antibodies, Monoclonal, Humanized; Asthma; Drug Administration Schedule; 3. Good health; Young Adult; 03 medical and health sciences; Double-Blind Method; Surveys and Questionnaires; Quality of Life; Humans; Female; Anti-Asthmatic Agents; Patient Reported Outcome Measures; Aged

Patients with severe, uncontrolled asthma experience frequent exacerbations and hospitalization, leading to poor health-related quality of life. In the phase 2b PATHWAY study (NCT02054130), tezepelumab reduced exacerbations by up to 71% and improved lung function, asthma control, and health-related quality of life vs placebo.This analysis further assessed the impact of tezepelumab on patient-reported outcomes (PROs) in PATHWAY.Adults with severe, uncontrolled asthma were randomized to subcutaneous tezepelumab (70 mg every 4 weeks, 210 mg every 4 weeks, or 280 mg every 2 weeks) or placebo for 52 weeks. PROs were assessed using the asthma control questionnaire-6 (ACQ-6) and the asthma quality of life questionnaire (standardized) for patients aged 12 years or older (AQLQ[S]+12). The proportions of responders (defined by improvements of ≥0.5 in ACQ-6 or AQLQ(S)+12 scores) and patients whose asthma was well-controlled, partially-controlled, or uncontrolled in the tezepelumab and placebo groups were identified. The Asthma Daily Diary questionnaire was used to assess changes in overall symptom severity.Overall, 550 patients were randomized. Up to 82% and 77% of tezepelumab-treated patients were ACQ-6 and AQLQ(S)+12 responders, respectively, compared with 70% and 64% of placebo-treated patients, respectively. The proportions of patients with well-controlled or partially-controlled asthma were higher in the tezepelumab-treated group than in the placebo group. In addition, tezepelumab improved the overall symptom severity.Tezepelumab treatment improved PROs vs placebo, as indicated by the higher proportion of ACQ-6 and AQLQ(S)+12 responders and improvements in symptom severity in the tezepelumab dose groups. These data further support the benefits of tezepelumab in patients with severe, uncontrolled asthma.